Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 63 of 88 · 4189 articles
A high-profile athlete describing recovery from ulcerative colitis and Crohn’s disease highlights that people with IBD can regain strength and return to demanding activities—something patients and families may find...
Anorectal stricture is a disabling Crohn’s complication that often requires surgery; a validated QoL threshold could help identify who should be prioritised for surgical review. This may make shared decision-making and...
This trial is testing guselkumab (an IL‑23 inhibitor) in a real‑world UC cohort and will measure endoscopic and histologic remission at 48 weeks — outcomes that matter to people managing moderate‑to‑severe ulcerative...
This trial is testing a new investigational antibody (XmAb942) specifically in people with moderately to severely active ulcerative colitis who have not responded to prior therapies. Early‑phase studies determine safety,...
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
This FDA label update affects people with IBD because tofacitinib is an approved JAK inhibitor for moderately to severely active ulcerative colitis and carries serious safety warnings that may influence treatment choices...
This report shows intestinal tuberculosis can present like inflammatory bowel disease with lower GI bleeding, leading to diagnostic delay; correct identification allowed targeted anti-TB and HIV therapy and clinical...
Cure8 found this source from Journal of physiological investigation, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. Open...
This meta-analysis suggests people with IBD face higher risks of major cardiovascular events (heart attack, ischemic heart disease, ischemic stroke), which may matter for monitoring and preventive care. Higher risk...
Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...
Noninvasive ultrasound could make assessment and monitoring of ulcerative colitis quicker and more accessible, including bedside evaluation and better rectal/pouch assessment with TPUS—potentially reducing reliance on...
This review summarizes many observational studies to identify dietary and environmental factors that may influence the risk of developing ulcerative colitis, which could help guide future research and prevention efforts...
The review suggests matrine and oxymatrine reduce inflammation and oxidative stress in animal UC models, pointing to potential new therapeutic approaches. People with UC may want to know about directions in preclinical...
Diet is a modifiable factor many people with IBD try to use to feel better. This review summarizes current evidence that a Mediterranean-style eating pattern may help quality of life and is linked to lower inflammation...
Noninvasive tools that reliably detect postoperative recurrence could reduce the need for frequent invasive endoscopy and help target earlier intervention for people with Crohn's disease after surgery.
This study looks at how statistically "fragile" results are in trials of new IBD treatments. Patients and clinicians should know that trial size, treatment type, and whether the result was a primary outcome affect how...
Fournier’s gangrene is a life-threatening infection that can occur in people with active intestinal inflammation or after perineal trauma; the case shows how rapidly it can progress and how many surgeries may be needed,...
This label update affects people with Crohn’s disease or ulcerative colitis because it spells out approved uses, age ranges, and the official dosing schedules and safety warnings for ustekinumab (STELARA). Changes in the...
Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Medications. The original article is from hmpgloballearningnetwork.com.
A pooled analysis found modest differences in cardiac structure and function in people with IBD versus controls, which may relate to the higher cardiovascular risk seen in this population.
The study suggests nickel accumulation and iron deficiency may be linked with more severe IBD. If confirmed, blood metal and micronutrient levels could help researchers understand disease mechanisms and guide nutritional...
If you or your clinician are considering dietary therapy like the CDED for Crohn's disease, microbiome features at baseline may influence who achieves sustained remission. Understanding these links could help personalize...
m6A RNA methylation regulators are emerging as potential targets that may influence immune-driven inflammation in diseases that matter to people with IBD. Understanding these pathways could point toward new precision...
Children with IBD commonly experience emotional and social challenges; residential camps appear to improve quality of life, confidence, disease knowledge, and reduce isolation, making them relevant as a supportive,...
Reactive TDM can help determine why a child with Crohn's disease is losing response to adalimumab and guide whether to escalate dose or switch biologics, which affects short-term management decisions.
The case suggests that blocking IL-4/IL-13 (with dupilumab) might rarely trigger Th17-predominant colonic inflammation presenting as ulcerative colitis; patients and clinicians should be alert for new GI symptoms after...
An ELANE mutation causing severe congenital neutropenia can present with neutropenic enterocolitis that mimics ulcerative colitis. Recognizing neutropenia and pursuing genetic testing can prevent misdiagnosis and change...
Links between IBD genetic risk and specific adult tissue lesion contexts help researchers understand which cell types and tissue programs may mediate inherited susceptibility. That can guide future biomarker and...
This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...
Rheumatological EIMs (notably joint inflammation) are frequent in IBD and affect quality of life; inconsistent definitions and lack of validated PROs make it harder for patients and clinicians to understand and compare...
New oral drugs that act mainly in the gut could offer more convenient options and potentially fewer systemic side effects for people with UC or Crohn’s disease. Early clinical signals and a planned Phase 2 trial mean...
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness. Open the original article for the...
Faster, more accurate capsule endoscopy reading could shorten diagnostic delays and reduce missed small‑bowel lesions in Crohn’s disease. For busy clinics, an AI assistant could cut review time and help less‑experienced...
Antibiotics can change the gut microbiome in ways that may raise IBD risk or worsen disease for some people. Knowing which antibiotic classes and approaches may be less harmful could help patients and clinicians reduce...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Genetic...
Risk-prediction tools like CDPATH™ could help people with Crohn’s disease and their doctors identify higher or lower short-term risk of complications and guide treatment conversations. This study tests how the tool...
Patients with UC often take multiple medicines that rely on CYP enzymes. This study is checking if afimkibart affects how those drugs are processed, which could matter for safety or dosing if the drug proceeds in...
A validated pre-endoscopic model could help estimate UC disease extent before colonoscopy, aiding clinical triage and planning without replacing endoscopy.
If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...
Digital self-management programs could help people with active IBD build skills to manage symptoms and quality of life between clinic visits. This trial tests whether such a program is feasible, acceptable, and practical...
Early intestinal ultrasound may predict one-year endoscopic remission in Crohn's disease, offering a noninvasive tool to guide treatment decisions and possibly reduce the need for some colonoscopies.
KTS can mimic ulcerative colitis with bloody diarrhea and colonic vascular lesions, so awareness may prevent misdiagnosis and guide appropriate multidisciplinary care. Early recognition can help address bleeding, anemia,...
Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.
This global survey shows that people with IBD prioritize symptom relief and psychological well-being over treatment features like administration route or speed of onset. That matters for shared decision-making, trial...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
If organoid transplantation can be translated to people, it could offer a new way to repair inflamed colonic lining and promote mucosal healing when current therapies are insufficient. The approach also highlights links...
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
The 1955 Truelove and Witts criteria do not account for patients already on modern outpatient therapies. Updated consensus criteria could change how ASUC is recognized and triaged in current clinical practice.
